Roch Doliveux, the chief executive of UCB SA, has been appointed chairman of the governing board of the Innovative Medicines Initiative, a public-private partnership that funds biomedical research in Europe. The IMI is a partnership between the European industry federation, Efpia, and the European Commission. It currently funds 30 projects with a combined budget of around €600 million. In addition to being CEO of UCB, Mr Doliveux is a member of the Efpia board of directors.
UCB SA announced the appointment on 7 March 2012.
Copyright 2012 Evernow Publishing Ltd